CHN’s Quest to Encourage Pharma Entry Continues Since the Chinese government brought a deluge of reforms to their pharmaceutical sector in 2018, it is no surprise 2019 is shaping up to be another game-changing year. Following their previous efforts to incentivize manufacturers to enter the Chinese market (easing evidence standards…
A brief history of NICE CBPartners’ take: The ultimate goal for both parties (manufacturers and NICE) is timely market access for patients as well as a return on investment. To achieve this there will need to be closer collaboration between both parties prior to receiving a recommendation about a new…
Summary The Central and Eastern Europe (CEE) region is attractive to drug manufacturers for its large cumulative population, evolving price and market access (P&MA) landscape, and relatively high willingness-to-pay (WTP) thresholds International Reference Pricing (IRP) policies continues to be one of the most important criteria in price decision-making in CEE…
Surveying the Field The story of CHN’s race to attract global investment into home-grown biotech begins in the USA. Since 2012, capital has flooded into the sector at unprecedented levels. Fueled by low interest rates and demand for high growth, USA biotech has experienced an explosion in private investment. Over…
SUMMARY Since the development of SINEMET in 1975, there has been little change in the standard of care for Parkinson’s disease given the high clinical failure rate of potential treatments partially driven by the inability of these compounds to pass the blood brain barrier Learning from the past failures, the…
SUMMARY Despite the high burden from Alzheimer’s disease, current therapies are only capable of managing the symptoms and experimental compounds designed to modify disease progression have failed clinical trials at an extremely high rate. The technologies available and capable of visualizing early AD signs are extremely expensive and there is…
SUMMARY Immunotherapies targeting the PD pathway have shown unprecedented efficacy in many oncology indications including NSCLC The scientific literature suggests that antibodies targeting PD-1 and PD-L1 have similar clinical data and class them together given that they similarly target the PD pathway, although the ability to show survival benefits in…
SUMMARY In 2018, Pfizer announced its plan to stop R&D activity in the central nervous system disease space and to create a venture fund that will invest in biotech firms conducting innovative neuroscience research The strategy of investing in a therapeutic space exclusively via corporate capital is coming into greater…
SUMMARY VC investment in digital healthcare has been growing rapidly (+42% vs. 2017) as the potential of new technology to solve complex issues, ranging from providing healthcare services to managing chronic conditions, evolves Most of these VC-backed digital healthcare companies aim to provide technology-enhanced solutions for providers and patients with…
Key Takeaways Vermont’s fledgling drug importation law has undergone preliminary savings analysis, with uninspiring projections of a 3.8% drug cost savings rate The importation program is unable to consider infused or biologic products, severely limiting the scope The state’s analysis admitted that the state Medicaid program is likely already receiving…